Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 2/20 | 0.42 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.42 |
| ▸ | CTSB | P07858 | 1/20 | 0.40 |
| ▸ | CTSS | P25774 | 1/20 | 0.40 |
| ▸ | CTSK | P43235 | 1/20 | 0.40 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.39 |
| ▸ | PPARG | P37231 | 2/20 | 0.39 |
| ▸ | PPARA | Q07869 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL451233 | 0.82 | MTNR1A (0.42) | MTNR1AMTNR1BFFAR1PPARGPPARA | |
| SCHEMBL14064862 | 0.81 | MCL1 (0.48) | CTSBCTSSCTSK | |
| SCHEMBL4965618 | 0.77 | FFAR1 (0.55) | MTNR1AMTNR1BFFAR1PPARG | |
| SCHEMBL448872 | 0.71 | PPARG (0.55) | PPARG | |
| SCHEMBL947200 | 0.70 | FFAR1 (0.59) | MTNR1AMTNR1BFFAR1PPARG | |
| SCHEMBL948541 | 0.69 | S1PR1 (0.48) | MTNR1AMTNR1BFFAR1PPARGPPARA | |
| SCHEMBL949121 | 0.69 | L3MBTL1 (0.50) | MTNR1AMTNR1BFFAR1PPARG | |
| SCHEMBL947719 | 0.69 | S1PR1 (0.70) | FFAR1PPARG | |
| SCHEMBL451234 | 0.69 | CA12 (0.46) | MTNR1AMTNR1BCTSBCTSSCTSK | |
| Hydrochloric Acid SCHEMBL3541048 | 0.68 | S1PR1 (0.68) | FFAR1PPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120064060-A1 | COMPOUND HAVING S1P RECEPTOR BINDING POTENCY AND USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2012-03-15 | — | — | US | disclosed |
| US-8039674-B2 | Amino-substituted cyclic compound for EDG-1(endothelial differentiation gene) and/or EDG-6-mediated diseases; transplant rejection, autoimmune diseases, allergies, asthma, multiple organ failure, ischemia, reperfusion injury, lung or liver fibrosis; antitumor agents | ONO PHARMACEUTICAL CO., LTD. (JP) | 2011-10-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120064060-A1 | COMPOUND HAVING S1P RECEPTOR BINDING POTENCY AND USE THEREOF | S1PR1, S1PR3, EDNRA | MTNR1A 219/4885MTNR1B 311/4885CTSB 3971/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.